Full Text View
Tabular View
No Study Results Posted
Related Studies
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Dana-Farber Cancer Institute.
Recruitment status was  Active, not recruiting
Study NCT00146588   Information provided by Dana-Farber Cancer Institute

First Received on September 6, 2005.   Last Updated on February 26, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Stage I Breast Cancer
Breast Cancer Stage II
Stage IIIA Breast Cancer
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Cyclophosphamide
Epirubicin
Capecitabine
Additional drug interventions recognized in this trial
Fluorouracil
More general drug interventions related to this trial
Alkylating Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Massachusetts General Hospital
Brigham and Women's Hospital
Beth Israel Deaconess Medical Center
Pharmacia


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services